arrow
H

Hilde Nilsen

Akershus University Hospital
H指数:41
被引数:1.5万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Neurogenic muscular atrophy in NHP2-related dyskeratosis congenita in a family: pathological and molecular insights

NHP2相关先天性角化不良症家族中的神经源性肌萎缩:病理学及分子学见解

2026-10-070
PRE
Digital home-based multimodal prehabilitation of colorectal cancer patients prior to surgery (the dHOPE study): a non-inferiority clinical trial protocol

数字家庭式多模态结直肠癌患者术前康复(dHOPE研究):一项非劣效性临床试验方案

2025-10-080
OAAI
Emerging strategies, applications and challenges of targeting NAD+ in the clinic

张 J, 王H-L, Lautrup S, Nilsen HL, Treebak JT, Watne LO, 等. 靶向NAD+的临床新兴策略、应用与挑战。Nat Aging. (2025). doi: 10.1038/s43587-025-00947-6

2025-09-090
PRE
SMUG1 DNA glycosylase modulates reward behaviour through regulation of olfactory receptor gene expression

SMUG1 DNA糖基化酶通过调控嗅觉受体基因表达来调节奖赏行为。

2025-08-121
OAAI
Nicotinamide riboside first alleviates symptoms but later downregulates dopamine metabolism in proteasome inhibition mouse model of Parkinson's disease

在帕金森病的蛋白酶体抑制小鼠模型中,烟酰胺核苷首先缓解症状,但随后下调多巴胺代谢

HELIYON
IF3.6
2024-07-010
OAAI
Complete response of metastatic microsatellite-stable BRAF V600E colorectal cancer to first-line oxaliplatin-based chemotherapy and immune checkpoint blockade

转移性微卫星稳定的BRAF V600E结直肠癌对基于奥沙利铂的一线化疗和免疫检查点阻断的完全反应

2024-06-280
OA
Predictive value of tumor mutational burden (TMB) in patients with metastatic microsatellite-stable (MSS) colorectal cancer (CRC) given first-line oxaliplatinbased chemotherapy and immune checkpoint blockade (ICB)
2024-03-220
PRE
Meeting Summary of The NYO3 5th NO-Age/AD Meeting and the 1st Norway-UK Joint Meeting on Aging and Dementia: Recent Progress on the Mechanisms and Interventional Strategies

NYO3第5届NO-Age/AD会议和第1届挪威-英国老龄化和痴呆症联席会议的会议摘要: 机制和干预策略的最新进展

2024-01-301
OAAI